BiotechTube

Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells

Phase 2Active
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

B-cell Acute Lymphoblastic Leukemia

Conditions

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory

Trial Timeline

Feb 1, 2022 → Dec 30, 2025

NCT ID
NCT06220097

About Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells

Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells is a phase 2 stage product being developed by CSPC Pharmaceutical Group Limited for B-cell Acute Lymphoblastic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT06220097. Target conditions include B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06220097Phase 2Active

Competing Products

20 competing products in B-cell Acute Lymphoblastic Leukemia

See all competitors
ProductCompanyStageHype Score
CD19-CAR-T cellsAvalon GloboCarePhase 1
25
Sepantronium BromideCothera BiosciencePhase 2
44
rituximabCelltrionPhase 1
33
Valemetostat tosylateDaiichi SankyoPhase 2
52
ASP2802 + MA-20Astellas PharmaPhase 1
33
ONTAK (denileukin diftitox)EisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
LOXO-338 + PirtobrutinibEli LillyPhase 1
33
PirtobrutinibEli LillyPre-clinical
23
Rituximab + GemcitabineEli LillyPhase 2
52
IbrutinibJohnson & JohnsonApproved
85
Ibrutinib 420 mg + Ibrutinib 560 mgJohnson & JohnsonApproved
85
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapyJohnson & JohnsonPhase 2
52
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + VincristineJohnson & JohnsonPhase 2
52
IbrutinibJohnson & JohnsonPre-clinical
23
SHR1459 tablet + Efavirenz tabletJiangsu Hengrui MedicinePhase 1
33
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52

Other Products from CSPC Pharmaceutical Group Limited

Butylphthalide + Butylphthalide placeboPhase 3
76
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinPhase 2
51
pegylated liposomal doxorubicin (PLD) + PD-1Phase 2
51
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabPhase 1/2
40